A study of neoadjuvant nab-paclitaxel followed by FEC for luminal B-like (HER2-negative) and triple-negative breast cancer
Phase 2
- Conditions
- uminal B-like (HER2-negative) or triple-negative operable breast cancer
- Registration Number
- JPRN-UMIN000017675
- Lead Sponsor
- Kyushu Breast Cancer Study Group (KBC-SG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- Female
- Target Recruitment
- 94
Inclusion Criteria
Not provided
Exclusion Criteria
1) clinically important cardiac disorder and past history of this 2) Severe medical disorders (uncontrolled DM, hypertension, renal failure, liver failure, clinically significant infection and mental disorders) 3) pregnant and nursing female 4) active double cancer 5) lung fibrosis and intestinal pneumonisa 6) allergy reaction for drugs is using in this study 7) Others
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pathological complete response rate based on subtype
- Secondary Outcome Measures
Name Time Method Breast conserving rates, response rates, safety, disease-free survival, overall survival, response rates of nab-paclitaxel,safety of nab-paclitaxel and identification of predictive factors for neoadjuvant chemotherapy and prognostic factors for patients after neoajuvant chemotherapy